Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The importance of combined radiation and endocrine therapy in locally advanced prostate cancer.

× No keyword cloud information.

18 in total

1. Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK.

Authors: Heather A Payne; David A Gillatt
Journal: BJU Int Date: 2007-03 Impact factor: 5.588

2. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer.

Authors: M Roach; A Chen; J Song; A Diaz; J Presti; P Carroll
Journal: Semin Urol Oncol Date: 2000-05

3. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

Authors: M V Pilepich; R Caplan; R W Byhardt; C A Lawton; M J Gallagher; J B Mesic; G E Hanks; C T Coughlin; A Porter; W U Shipley; D Grignon
Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544

4. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors: Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal: Urology Date: 2007-06 Impact factor: 2.649

5. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Authors: M Roach; M DeSilvio; C Lawton; V Uhl; M Machtay; M J Seider; M Rotman; C Jones; S O Asbell; R K Valicenti; S Han; C R Thomas; W S Shipley
Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544

6. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal: JAMA Date: 1998-09-16 Impact factor: 56.272

7. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Authors: Colleen A Lawton; Michelle DeSilvio; Mack Roach; Valery Uhl; Robert Kirsch; Michael Seider; Marvin Rotman; Christopher Jones; Sucha Asbell; Richard Valicenti; Stephen Hahn; Charles R Thomas
Journal: Int J Radiat Oncol Biol Phys Date: 2007-05-24 Impact factor: 7.038

8. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Authors: Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544

9. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Authors: Matthew R Cooperberg; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll
Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544

10. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors: Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal: Lancet Date: 2011-11-02 Impact factor: 79.321

2 in total

1. The opportunity cost of androgen suppression in locally advanced prostate cancer.

Authors: Phillip J Gray; Jason A Efstathiou; William U Shipley
Journal: Asian J Androl Date: 2013-02-25 Impact factor: 3.285

2. Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer.

Authors: Xu-Dong Yao; Xiao-Jun Liu; Shi-Lin Zhang; Bo Dai; Hai-Liang Zhang; Ding-Wei Ye
Journal: Asian J Androl Date: 2012-12-10 Impact factor: 3.285

2 in total